| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Ansa Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $119.54M | Series C-1 | 10/16/2026 | $37.88M | $149.35M | $0.11 | Undisclosed Investors | ||||
 | Antares Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.72M | Series A-2 | 6/10/2025 | $139.29M | $289.7M | $1.00 | Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, Cormorant Asset Management, Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, Willett Advisors | ||||
 | ARS Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $76.55M | Series D | 8/31/2021 | $55M | $310.11M | $5.89 | SR One, RA Capital Management, Deerfield | ||||
 | Bicara Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $710.05M | Series C | 12/12/2023 | $165M | $495.55M | $1.38 | Braidwell LP, TPG, The Rise Fund, Deerfield Management, Fairmount, Aisling Capital, Red Tree Venture Capital, RA Capital Management, F-Prime Capital, Eight Roads Ventures, Invus Piper Heartland Healthcare Capital, Premji Invest, Omega Funds, Bioqube Ventures, Acorn Bioventures, Janus Henderson Investors | ||||
 | BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170M | $440.23M | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | ||||
 | CareCloud | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $98.59M | Series C | 12/5/2016 | $28.05M | $97.11M | $1.20 | Intel Capital, Norwest Capital Partners, Tenaya Capital, Adams Street Partners, Blue Cloud Ventures, First Data, PNC | ||||
 | Doceree | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $45.11M | Series B-2 | 9/27/2023 | $7.5M | $271.1M | $104.20 | Creaegis, Eight Roads Ventures, F-Prime Capital | ||||
 | eFFECTOR Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $152.08M | Series C | 8/24/2017 | $39.1M | $197.73M | $0.51 | Pfizer Venture Investments, Alexandria Venture Investments, U.S. Venture Partners, Abingworth, Novartis Venture Fund, SR One, The Column Group, Altitude Life Science Ventures, Sectoral Asset Management, Abbvie Biotech Ventures, BioMed Ventures, Astellas Ventures | ||||
 | Electra Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $302.9M | Series C | 10/22/2025 | $184.13M | $460.97M | $10.15 | Nextech, EQT Life Sciences, Sanofi, HBM Healthcare Investments, Mubadala Capital, OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital, RA Capital Management | ||||
 | ElectraDx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $46.77M | Series B | 11/14/2025 | $32M | $270.54M | $7.31K | TAUNS Laboratories | ||||
 | Elligo Health Research | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $213.37M | Series E-1 | 9/23/2021 | $34.87M | $392.04M | $1.99 | Morgan Stanley Expansion Capital, Ally Bridge Group, Norwest Venture Partners, Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler, Shumway Capital, Syneos Health | ||||
 | Epic Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $606.66M | Series A-3 | 12/29/2023 | $20.9M | $94.14M | $3.00 | Undisclosed Investors | ||||
 | Geneoscopy | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.58M | Series C | 1/8/2025 | $79.05M | $447.85M | $4.13 | Bio-Rad Laboratories, Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management, Mercy Health, Tri Locum Partners | ||||
 | Healthie | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $39.78M | Series B | 10/15/2024 | $23M | $273.02M | $11.77 | TCV, Birchmere Ventures, Velvet Sea Ventures, Greymatter, Watershed | ||||
 | Inflammatix | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $186.19M | Series E-2 | 9/12/2024 | $26.2M | $210.31M | $0.15 | Khosla Ventures, Think.Health Ventures, Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare Ventures, RAW Ventures | ||||
 | Marea | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190M | Series B | 6/18/2024 | $152.89M | $267.31M | $1.45 | Sofinnova Investments, Forbion Capital Partners, Perceptive Advisors, venBio, Alpha Wave Global, Omega Funds, Citadel, Third Rock Ventures | ||||
 | MBX Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $216.64M | Series C | 8/5/2024 | $63.5M | $316.71M | $1.03 | Deep Track Capital, Driehaus Capital Management, T. Rowe Price Associates, Frazier Life Sciences, OrbiMed, Wellington Management | ||||
 | Modern Animal | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $239.65M | Series D | 9/16/2025 | $46M | $142.25M | $1.61 | Addition, True Ventures, Upfront Ventures, Founders Fund | ||||
 | Neuron23 | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $310.11M | Series D | 6/24/2025 | $96.5M | $331.2M | $0.99 | Westlake Village BioPartners, SoftBank, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments, Acorn Bioventures | ||||
 | Pact Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $354.6M | Series D | 9/30/2022 | $104.1M | $132.98M | $0.07 | Undisclosed Investors | ||||
 | Phlow | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $96.11M | Series C-1 | 7/22/2025 | $34.88M | $417.6M | $18.09 | Align Private Capital | ||||
 | Qnovia | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $49.64M | Series B | 12/10/2024 | $8M | $246.21M | $19.32 | Blue Ledge Capital, Evolution VC Partners, Vice Ventures, Gaingels | ||||
 | Redox Engine | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $96.31M | Series D | 2/24/2021 | $45.5M | $310.5M | $4.45 | Adams Street Partners, Avenir, Battery Ventures, .406 Ventures, RRE Ventures | ||||
 | Verge Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.53M | Series C* | 9/8/2023 | $42M | $403.75M | $7.19 | Alexion, AstraZeneca, Alumni Ventures, Tenmile | ||||